According to 3 multicenter, randomized, double-blind, placebo-controlled obesity trials (BMI 30, or BMI 27 with at least 1 comorbidity of hypertension, dyslipidemia, or type 2 diabetes) conducted to evaluate the effect of CONTRAVE in conjunction with reduced caloric intake and increased physical activity, the average percentage of weight loss in patients at 56 weeks ranged from 3.7% to 8.1% with CONTRAVE, compared to 1.3% to 4.9% with placebo
You can take the free assessment quiz to begin
Nathaly del Carmen, a marketing manager in New York, claims that "at least one person at her table" is on a GLP-1 drug "whenever she dines out," said the Times
The FDA has since resolved both shortages, tightening but not fully closing that window
This dynamic process is supported by clinical research
Tell your provider about all medicines and supplements you take